Clinical Trial Update: Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab [Phase 2]

View source ↗

Summary

Phase 2 trial of cetuximab, capecitabine, and oxaliplatin with or without bevacizumab in colorectal neoplasms was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Cetuximab (cetuximab)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Colorectal Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2022-01-12